1. Academic Validation
  2. Taccalonolide C-6 Analogues, Including Paclitaxel Hybrids, Demonstrate Improved Microtubule Polymerizing Activities

Taccalonolide C-6 Analogues, Including Paclitaxel Hybrids, Demonstrate Improved Microtubule Polymerizing Activities

  • J Nat Prod. 2021 Jun 25;84(6):1799-1805. doi: 10.1021/acs.jnatprod.1c00211.
April L Risinger 1 2 Shayne D Hastings 1 Lin Du 3 4
Affiliations

Affiliations

  • 1 Department of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229-3900, United States.
  • 2 Mays Cancer Center, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229-3900, United States.
  • 3 Department of Chemistry and Biochemistry, The University of Oklahoma, Norman, Oklahoma 73019-5251, United States.
  • 4 Institute for Natural Products Applications and Research Technologies, The University of Oklahoma, Norman, Oklahoma 73019-5251, United States.
Abstract

The C-22,23-epoxy taccalonolides are microtubule stabilizers that bind covalently to β-tubulin with a high degree of specificity. We semisynthesized and performed biochemical and cellular evaluations on 20 taccalonolide analogues designed to improve target engagement. Most notably, modification of C-6 on the taccalonolide backbone with the C-13 N-acyl-β-phenylisoserine side chain of paclitaxel provided compounds with 10-fold improved potency for biochemical tubulin polymerization as compared to that of the unmodified epoxy taccalonolide AJ. Covalent docking demonstrated that the C-13 paclitaxel side chain occupied a binding pocket adjacent to the core taccalonolide pocket near the M-loop of β-tubulin. Although paclitaxel-taccalonolide hybrids demonstrated improved in vitro biochemical potency, they retained features of the taccalonolide chemotype, including a lag in tubulin polymerization and high degree of cellular persistence after drug washout associated with covalent binding. Together, these data demonstrate that C-6 modifications can improve the target engagement of this covalent class of microtubule drugs without substantively changing their mechanism of action.

Figures